Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Sponsor: RedHill Biopharma Limited
This PHASE2 trial investigates Irritable Bowel Syndrome With Diarrhea and is currently completed. RedHill Biopharma Limited leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .